Drug safety group petitions FDA to block marketing of unapproved compounded peptides; bipartisan bill seeks clinical trial reforms

A drug safety advocacy group has filed a citizen petition with the FDA, asking the agency to stop the marketing of compounded peptide products that lack approval.

A bipartisan group of lawmakers has introduced a bill intended to improve participation in clinical trials and streamline the review process, aiming to make trials more accessible and efficient.

These moves illustrate continued efforts to tighten oversight of drug manufacturing and to modernize the clinical trial system, highlighting the FDA’s role in protecting public health.